STELARA SQ® (Ustekinumab) is an immunosuppressive drug that reduces inflammation in the body due to various autoimmune diseases.
STELARA SQ® is manufactured by Janssen Biotech.
Administration and Dosage:
For patients with Crohn’s disease, administration of STELARA is a regimen 1 intravenous infusion therapy followed by a maintenance dose of subcutaneous injections every 8 weeks. Patients with Plaque Psoriasis and Psoriatic Arthritis, STELARA is administred subcutaneously at week 1 and then week 4, followed by every 12 weeks regimen.
Common Side Effects:
The more common side effects of STELARA SQ® include serious infections, which may require hospitalization, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses.
Ready to Schedule an Appointment?
Please CLICK HERE to get started.
STELARA SQ® is indicated to treat:
- Crohn’s Disease
- Plaque Psoriasis
- Psoriatic Arthritis